Browse News
Filter News
Found 40,381 articles
-
Keep up with the regulator's latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
In honor of World Cancer Research Day, BioSpace takes a deep dive into 10 therapeutic candidates with the potential to change the treatment landscape in lung, breast, colorectal cancer and more.
-
Qihan Biotech announces the completion of pre-Series B financing for developing stem cell-derived cell therapy products with high-throughput multiplexable genome editing
9/22/2023
Hangzhou Qihan Biotech Co., Ltd. today announced the successful completion of a pre-Series B financing exceeding $16 million funded by a new investor, Zhejiang Industrial Fund Co., Ltd., with participation from other existing investors.
-
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
9/22/2023
Coya Therapeutics, Inc. today announced licensing of the exclusive, worldwide rights of a proprietary Exosome Engineering Technology from CMU with potential applications across multiple indications, including neurodegeneration, autoimmune, and oncology.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Transcend Therapeutics and Yale awarded U.S. Department of Defense grant to study methylone for PTSD
9/21/2023
Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on methylone – Transcend's lead compound for the treatment of post-traumatic stress disorder (PTSD).
-
Prime Therapeutics Appoints New Chief Compliance Officer
9/21/2023
Prime Therapeutics LLC/Magellan Rx announces Tizgel High as chief compliance officer.
-
Lynk Pharmaceuticals Completes Series C2 Financing Round, with Total C Round Funding of 322 Million RMB
9/21/2023
Lynk Pharmaceuticals Co., Ltd. today announced the successful completion of Series C2 financing.
-
Osteal Therapeutics Closes $23M Series C Financing
9/21/2023
Osteal Therapeutics, Inc. announced today the completion of an oversubscribed $23 million Series C equity financing.
-
ReNAgade Therapeutics Named to the 2023 Endpoints 11
9/21/2023
ReNAgade Therapeutics today announced that it has been named as one of the Endpoints 11 companies of 2023, awarded by Endpoints News editor John Carroll to the most promising private biotechnology companies in the industry.
-
Actylis Launches a New cGMP WFI Generation, Storage, and Distribution System with Additional ISO Class 7 Manufacturing Space as Part of Its Continued Commitment to Supporting Biopharmaceutical Manufacturing
9/21/2023
Actylis, a leading global manufacturer of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, announced the launch of Water for Injection and additional ISO Class 7 manufacturing space at its Baie d’Urfé site in Montreal, Canada.
-
NeurAxis Reports Second Quarter 2023 Financial Results
9/21/2023
NeurAxis, Inc., a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, reported financial results for the second quarter ended June 30, 2023.
-
Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors
9/21/2023
Maxion Therapeutics, the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, announced the appointment of senior industry leader Eva-Lotta Allan as the Chair of its Board of Directors.
-
DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)
9/21/2023
DermTech, Inc. announced that DermTech’s Compensation Committee has granted an equity award to its new chief commercial officer, Mark Aguillard.
-
AVS Opens Global Headquarters in Boston’s Seaport District to Support Growth
9/21/2023
AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, announced the opening of its new global headquarters at 451 D Street in Boston, Mass.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 21, 2023
9/21/2023
Avidity Biosciences, Inc. announced that on September 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 90,300 shares of its common stock and 45,150 restricted stock units to nine new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company
9/21/2023
Oramed Pharmaceuticals Inc. announced that on September 21, 2023, Oramed and Scilex Holding Company entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note to Oramed.
-
Breakthrough Properties to Develop New European Headquarters for Neogene Therapeutics
9/21/2023
Breakthrough Properties, a premier global life sciences real estate developer, announced that it has reached an agreement with Neogene Therapeutics to develop its new European headquarters within the campus of the Amsterdam University Medical Center (Amsterdam UMC), one of Europe's leading medical institutions.
-
Bringing in an additional $50 million in a Series B extension, ReCode Therapeutics’ total haul for the funding round totaled $260 million, which it will use to further its experimental mRNA therapies.
-
The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.